Alpha-1 Antitrypsin Deficiency: The Genetic Cause of Lung and Liver Disease That's Routinely Missed

Often mistaken for regular COPD or asthma — this inherited condition can damage lungs and liver, and smoking makes it far worse.

Alpha-1 antitrypsin deficiency is an inherited condition that damages the lungs and liver — and it's frequently mistaken for ordinary COPD or asthma for years before anyone thinks to test for it. Knowing your SERPINA1 status can change how you protect your lungs, especially if you smoke or are around lung irritants.

What the SERPINA1 gene does

Alpha-1 antitrypsin (AAT) is a protein made mainly in the liver that circulates to the lungs, where it acts as a protective shield. Its job is to neutralize an enzyme (neutrophil elastase) that would otherwise chew up delicate lung tissue during normal immune activity. The SERPINA1 gene codes for AAT.

Certain SERPINA1 variants — most importantly the "Z" allele — cause the protein to misfold. Two problems follow:

• In the lungs: too little functional AAT reaches them, so the protective shield is weak. Lung tissue is gradually destroyed, causing early emphysema (a form of COPD), often decades earlier than smoking alone would.
• In the liver: the misfolded protein gets stuck inside liver cells instead of being secreted, where it can accumulate and cause liver damage — sometimes appearing in childhood, sometimes in adulthood.

Why it hides for so long

Shortness of breath, wheezing and chronic cough are extremely common and usually chalked up to asthma, smoking, or "just getting older." Alpha-1 looks exactly like those conditions on the surface. The tells that should raise suspicion:

• Emphysema/COPD at a young age (say, 40s) — especially with limited or no smoking history.
• COPD that affects the lower parts of the lungs (smoking-related emphysema tends to hit the upper lobes).
• Unexplained liver disease, in a child or adult, particularly alongside lung problems.
• A family history of early lung or liver disease.

Why the genetic answer is worth having early

Alpha-1 is progressive and the lung damage it causes is irreversible — but the rate of damage is heavily modifiable. Someone who learns they carry two Z alleles at 30 and never smokes has a very different trajectory than someone who finds out at 55 after years of smoking. Early knowledge also means:

• Baseline lung function testing and monitoring over time.
• Liver monitoring, since the liver risk is independent of the lung risk.
• Access to specialist care and, for appropriate patients, AAT augmentation therapy (infusions of the protein).
• Family screening — this is inherited, so relatives may carry it too.

Carriers vs. affected

Genotype nuance matters. People with one normal and one Z allele (often written PiMZ) are usually carriers with milder or no direct disease, though smoking may still add some risk. The classic severe deficiency comes from two deficiency alleles (PiZZ being the most studied). A genetic result should be interpreted with a clinician who understands these combinations and can order the confirmatory blood test that measures actual AAT levels.

What to do with a result

1. Confirm with a blood AAT level test ordered by your doctor.
2. If affected, never smoke — and minimize exposure to dust, fumes and pollution.
3. Get baseline lung function testing and periodic monitoring.
4. Ask about liver evaluation, since liver involvement is separate from lung involvement.
5. Consider an Alpha-1 specialist center for higher-risk genotypes.

This article is for general educational purposes only and is not medical advice. Genetic results should be interpreted with a qualified healthcare provider or genetic counselor. Do not start, stop, or change any medication or treatment based on this article.